Atrinsic (NASDAQ:PTIX) Upgraded at Wall Street Zen

Atrinsic (NASDAQ:PTIX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Atrinsic Stock Down 3.0%

Shares of NASDAQ PTIX opened at $3.22 on Friday. The firm has a market capitalization of $1.90 million, a P/E ratio of -0.34 and a beta of 0.36. The stock’s 50-day simple moving average is $3.26 and its two-hundred day simple moving average is $3.64. Atrinsic has a twelve month low of $2.25 and a twelve month high of $15.26.

Atrinsic (NASDAQ:PTIX) last announced its earnings results on Wednesday, September 10th. The company reported ($1.37) earnings per share for the quarter.

About Atrinsic

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.